TY - JOUR AU - Ogdie, A. AU - Weiss, P. PY - 2015 DA - 2015// TI - The epidemiology of psoriatic arthritis JO - Rheum Dis Clin N Am VL - 41 UR - https://doi.org/10.1016/j.rdc.2015.07.001 DO - 10.1016/j.rdc.2015.07.001 ID - Ogdie2015 ER - TY - JOUR AU - Coates, L. C. AU - Helliwell, P. S. PY - 2016 DA - 2016// TI - Treating to target in psoriatic arthritis: how to implement in clinical practice JO - Ann Rheum Dis VL - 75 UR - https://doi.org/10.1136/annrheumdis-2015-208617 DO - 10.1136/annrheumdis-2015-208617 ID - Coates2016 ER - TY - JOUR AU - Coates, L. C. AU - Kavanaugh, A. AU - Mease, P. J. AU - Soriano, E. R. AU - Laura Acosta-Felquer, M. L. AU - Armstrong, A. W. PY - 2016 DA - 2016// TI - Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis JO - Arthritis Rheumatol. VL - 68 ID - Coates2016 ER - TY - JOUR AU - Gossec, L. AU - Baraliakos, X. AU - Kerschbaumer, A. AU - Wit, M. AU - McInnes, I. AU - Dougados, M. PY - 2020 DA - 2020// TI - EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update JO - Ann Rheum Dis VL - 79 UR - https://doi.org/10.1136/annrheumdis-2020-217159 DO - 10.1136/annrheumdis-2020-217159 ID - Gossec2020 ER - TY - STD TI - National Psoriasis Foundation. (2019) https://www.psoriasis.org/content/methotrexate-0. Accessed 01 May 2020. UR - https://www.psoriasis.org/content/methotrexate-0 ID - ref5 ER - TY - JOUR AU - Ianculescu, I. AU - Weisman, M. H. PY - 2015 DA - 2015// TI - The role of methotrexate in psoriatic arthritis: what is the evidence? JO - Clin Exp Rheumatol VL - 33 ID - Ianculescu2015 ER - TY - JOUR AU - Kingsley, G. H. AU - Kowalczyk, A. AU - Taylor, H. AU - Ibrahim, F. AU - Packham, J. C. AU - McHugh, N. J. PY - 2012 DA - 2012// TI - A randomized placebo-controlled trial of methotrexate in psoriatic arthritis JO - Rheumatology (Oxford) VL - 51 UR - https://doi.org/10.1093/rheumatology/kes001 DO - 10.1093/rheumatology/kes001 ID - Kingsley2012 ER - TY - JOUR AU - Antoni, C. AU - Krueger, G. G. AU - Vlam, K. AU - Birbara, C. AU - Beutler, A. AU - Guzzo, C. PY - 2005 DA - 2005// TI - Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial JO - Ann Rheum Dis VL - 64 UR - https://doi.org/10.1136/ard.2004.032268 DO - 10.1136/ard.2004.032268 ID - Antoni2005 ER - TY - JOUR AU - Behrens, F. AU - Canete, J. D. AU - Olivieri, I. AU - Kuijk, A. W. AU - McHugh, N. AU - Combe, B. PY - 2015 DA - 2015// TI - Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature JO - Rheumatology (Oxford) VL - 54 UR - https://doi.org/10.1093/rheumatology/keu415 DO - 10.1093/rheumatology/keu415 ID - Behrens2015 ER - TY - JOUR AU - Fagerli, K. M. AU - Lie, E. AU - Heijde, D. AU - Heiberg, M. S. AU - Lexberg, A. S. AU - Rodevand, E. PY - 2014 DA - 2014// TI - The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2012-202347 DO - 10.1136/annrheumdis-2012-202347 ID - Fagerli2014 ER - TY - JOUR AU - Behrens, F. AU - Koehm, M. AU - Arndt, U. AU - Wittig, B. M. AU - Greger, G. AU - Thaci, D. PY - 2016 DA - 2016// TI - Does concomitant methotrexate with adalimumab influence treatment outcomes in patients with psoriatic arthritis? Data from a large observational study JO - J Rheumatol VL - 43 UR - https://doi.org/10.3899/jrheum.141596 DO - 10.3899/jrheum.141596 ID - Behrens2016 ER - TY - JOUR AU - Mease, P. J. AU - Collier, D. H. AU - Saunders, K. C. AU - Li, G. AU - Kremer, J. M. AU - Greenberg, J. D. PY - 2015 DA - 2015// TI - Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry JO - RMD Open VL - 1 UR - https://doi.org/10.1136/rmdopen-2015-000181 DO - 10.1136/rmdopen-2015-000181 ID - Mease2015 ER - TY - JOUR AU - Combe, B. AU - Behrens, F. AU - McHugh, N. AU - Brock, F. AU - Kerkmann, U. AU - Kola, B. PY - 2016 DA - 2016// TI - Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials JO - J Rheumatol VL - 43 UR - https://doi.org/10.3899/jrheum.151290 DO - 10.3899/jrheum.151290 ID - Combe2016 ER - TY - JOUR AU - Glintborg, B. AU - Ostergaard, M. AU - Dreyer, L. AU - Krogh, N. S. AU - Tarp, U. AU - Hansen, M. S. PY - 2011 DA - 2011// TI - Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry JO - Arthritis Rheum VL - 63 UR - https://doi.org/10.1002/art.30117 DO - 10.1002/art.30117 ID - Glintborg2011 ER - TY - JOUR AU - Mease, P. J. AU - Gladman, D. D. AU - Collier, D. H. AU - Ritchlin, C. T. AU - Helliwell, P. S. AU - Liu, L. PY - 2019 DA - 2019// TI - Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial JO - Arthritis Rheumatol VL - 71 UR - https://doi.org/10.1002/art.40851 DO - 10.1002/art.40851 ID - Mease2019 ER - TY - JOUR AU - Liu, L. AU - Lu, J. AU - Allan, B. W. AU - Tang, Y. AU - Tetreault, J. AU - Chow, C. K. PY - 2016 DA - 2016// TI - Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A JO - J Inflamm Res VL - 9 UR - https://doi.org/10.2147/JIR.S100940 DO - 10.2147/JIR.S100940 ID - Liu2016 ER - TY - STD TI - Taltz (ixekizumab) prescribing information. Indianapolis: Eli Lilly and Company; 2019. ID - ref17 ER - TY - STD TI - European Medicines Agency. Taltz. 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/taltz. Accessed 01 May 2020. UR - https://www.ema.europa.eu/en/medicines/human/EPAR/taltz ID - ref18 ER - TY - JOUR AU - Mease, P. J. AU - Heijde, D. AU - Ritchlin, C. T. AU - Okada, M. AU - Cuchacovich, R. S. AU - Shuler, C. L. PY - 2017 DA - 2017// TI - Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 JO - Ann Rheum Dis VL - 76 UR - https://doi.org/10.1136/annrheumdis-2016-209709 DO - 10.1136/annrheumdis-2016-209709 ID - Mease2017 ER - TY - JOUR AU - Nash, P. AU - Kirkham, B. AU - Okada, M. AU - Rahman, P. AU - Combe, B. AU - Burmester, G. R. PY - 2017 DA - 2017// TI - Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial JO - Lancet. VL - 389 UR - https://doi.org/10.1016/S0140-6736(17)31429-0 DO - 10.1016/S0140-6736(17)31429-0 ID - Nash2017 ER - TY - JOUR AU - Coates, L. C. AU - Kishimoto, M. AU - Gottlieb, A. AU - Shuler, C. L. AU - Lin, C. Y. AU - Lee, C. H. PY - 2017 DA - 2017// TI - Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naive patients with active psoriatic arthritis (PsA): results from SPIRIT-P1 JO - RMD Open. VL - 3 UR - https://doi.org/10.1136/rmdopen-2017-000567 DO - 10.1136/rmdopen-2017-000567 ID - Coates2017 ER - TY - JOUR AU - Nash, P. AU - Behrens, F. AU - Orbai, A. M. AU - Rathmann, S. S. AU - Adams, D. H. AU - Benichou, O. PY - 2018 DA - 2018// TI - Erratum to: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors JO - RMD Open VL - 4 UR - https://doi.org/10.1136/rmdopen-2018-000692 DO - 10.1136/rmdopen-2018-000692 ID - Nash2018 ER - TY - JOUR AU - Felson, D. T. AU - Anderson, J. J. AU - Boers, M. AU - Bombardier, C. AU - Furst, D. AU - Goldsmith, C. PY - 1995 DA - 1995// TI - American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis JO - Arthritis Rheum VL - 38 UR - https://doi.org/10.1002/art.1780380602 DO - 10.1002/art.1780380602 ID - Felson1995 ER - TY - JOUR AU - Coates, L. C. AU - Fransen, J. AU - Helliwell, P. S. PY - 2010 DA - 2010// TI - Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment JO - Ann Rheum Dis VL - 69 UR - https://doi.org/10.1136/ard.2008.102053 DO - 10.1136/ard.2008.102053 ID - Coates2010 ER - TY - JOUR AU - Coates, L. C. AU - Helliwell, P. S. PY - 2010 DA - 2010// TI - Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data JO - Arthritis Care Res (Hoboken) VL - 62 UR - https://doi.org/10.1002/acr.20155 DO - 10.1002/acr.20155 ID - Coates2010 ER - TY - JOUR AU - Mease, P. J. PY - 2011 DA - 2011// TI - Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander/Newcastle Enthesitis index (MEI), Leeds Enthesitis index (LEI), spondyloarthritis research Consortium of Canada (SPARCC), Maastricht ankylosing spondylitis Enthesis score (MASES), Leeds Dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI) JO - Arthritis Care Res (Hoboken) VL - 63 UR - https://doi.org/10.1002/acr.20577 DO - 10.1002/acr.20577 ID - Mease2011 ER - TY - JOUR AU - Schoels, M. M. AU - Aletaha, D. AU - Alasti, F. AU - Smolen, J. S. PY - 2016 DA - 2016// TI - Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score JO - Ann Rheum Dis VL - 75 UR - https://doi.org/10.1136/annrheumdis-2015-207507 DO - 10.1136/annrheumdis-2015-207507 ID - Schoels2016 ER - TY - JOUR AU - Kay, J. AU - Matteson, E. L. AU - Dasgupta, B. AU - Nash, P. AU - Durez, P. AU - Hall, S. PY - 2008 DA - 2008// TI - Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study JO - Arthritis Rheum VL - 58 UR - https://doi.org/10.1002/art.23383 DO - 10.1002/art.23383 ID - Kay2008 ER - TY - JOUR AU - Scheinfeld, N. PY - 2004 DA - 2004// TI - Off-label uses and side effects of infliximab JO - J Drugs Dermatol VL - 3 ID - Scheinfeld2004 ER - TY - JOUR AU - Gottlieb, A. AU - Korman, N. J. AU - Gordon, K. B. AU - Feldman, S. R. AU - Lebwohl, M. AU - Koo, J. Y. PY - 2008 DA - 2008// TI - Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics JO - J Am Acad Dermatol VL - 58 UR - https://doi.org/10.1016/j.jaad.2008.02.040 DO - 10.1016/j.jaad.2008.02.040 ID - Gottlieb2008 ER - TY - JOUR AU - Ritchlin, C. T. AU - Kavanaugh, A. AU - Gladman, D. D. AU - Mease, P. J. AU - Helliwell, P. AU - Boehncke, W. H. PY - 2009 DA - 2009// TI - Treatment recommendations for psoriatic arthritis JO - Ann Rheum Dis VL - 68 UR - https://doi.org/10.1136/ard.2008.094946 DO - 10.1136/ard.2008.094946 ID - Ritchlin2009 ER - TY - JOUR AU - Baranauskaite, A. AU - Raffayova, H. AU - Kungurov, N. V. AU - Kubanova, A. AU - Venalis, A. AU - Helmle, L. PY - 2012 DA - 2012// TI - Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study JO - Ann Rheum Dis VL - 71 UR - https://doi.org/10.1136/ard.2011.152223 DO - 10.1136/ard.2011.152223 ID - Baranauskaite2012 ER - TY - JOUR AU - Mease, P. J. AU - Kivitz, A. J. AU - Burch, F. X. AU - Siegel, E. L. AU - Cohen, S. B. AU - Ory, P. PY - 2004 DA - 2004// TI - Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression JO - Arthritis Rheum VL - 50 UR - https://doi.org/10.1002/art.20335 DO - 10.1002/art.20335 ID - Mease2004 ER - TY - JOUR AU - Mease, P. J. AU - Fleischmann, R. AU - Deodhar, A. A. AU - Wollenhaupt, J. AU - Khraishi, M. AU - Kielar, D. PY - 2014 DA - 2014// TI - Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2013-203696 DO - 10.1136/annrheumdis-2013-203696 ID - Mease2014 ER - TY - JOUR AU - Gladman, D. D. AU - Mease, P. J. AU - Ritchlin, C. T. AU - Choy, E. H. AU - Sharp, J. T. AU - Ory, P. A. PY - 2007 DA - 2007// TI - Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial JO - Arthritis Rheum VL - 56 UR - https://doi.org/10.1002/art.22379 DO - 10.1002/art.22379 ID - Gladman2007 ER - TY - JOUR AU - Kirkham, B. AU - Mease, P. J. AU - Nash, P. AU - Balsa, A. AU - Combe, B. AU - Rech, J. PY - 2018 DA - 2018// TI - AB0945 Secukinumab efficacy in patients with active psoriatic arthritis: pooled analysis of four phase 3 trials by prior anti-tnf therapy and concomitant methotrexate use JO - Ann Rheum Dis VL - 77 ID - Kirkham2018 ER - TY - JOUR AU - Choquette, D. AU - Bessette, L. AU - Sauvageau, L. C. AU - Ferdinand, I. AU - Haraoui, P. AU - Massicotte, F. PY - 2019 DA - 2019// TI - AB0740 use of secukinumab in patients with psoriatic arthritis. Impacts of combination with methotrexate JO - Ann Rheum Dis VL - 78 ID - Choquette2019 ER - TY - JOUR AU - McInnes, I. B. AU - Mease, P. J. AU - Ritchlin, C. T. AU - Rahman, P. AU - Gottlieb, A. B. AU - Kirkham, B. PY - 2017 DA - 2017// TI - Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study JO - Rheumatology (Oxford) VL - 56 UR - https://doi.org/10.1093/rheumatology/kex301 DO - 10.1093/rheumatology/kex301 ID - McInnes2017 ER - TY - JOUR AU - Mease, P. AU - Roussou, E. AU - Burmester, G. R. AU - Goupille, P. AU - Gottlieb, A. AU - Moriarty, S. R. PY - 2019 DA - 2019// TI - Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials JO - Arthritis Care Res (Hoboken) VL - 71 UR - https://doi.org/10.1002/acr.23738 DO - 10.1002/acr.23738 ID - Mease2019 ER - TY - JOUR AU - Langley, R. G. AU - Kimball, A. B. AU - Nak, H. AU - Xu, W. AU - Pangallo, B. AU - Osuntokun, O. O. PY - 2019 DA - 2019// TI - Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials JO - J Eur Acad Dermatol Venereol VL - 33 UR - https://doi.org/10.1111/jdv.15242 DO - 10.1111/jdv.15242 ID - Langley2019 ER - TY - JOUR AU - Cuchacovich, R. AU - Perez-Alamino, R. AU - Garcia-Valladares, I. AU - Espinoza, L. R. PY - 2012 DA - 2012// TI - Steps in the management of psoriatic arthritis: a guide for clinicians JO - Ther Adv Chronic Dis VL - 3 UR - https://doi.org/10.1177/2040622312459673 DO - 10.1177/2040622312459673 ID - Cuchacovich2012 ER - TY - JOUR AU - Lecluse, L. L. AU - Driessen, R. J. AU - Spuls, P. I. AU - Jong, E. M. AU - Stapel, S. O. AU - Doorn, M. B. PY - 2010 DA - 2010// TI - Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis JO - Arch Dermatol VL - 146 UR - https://doi.org/10.1001/archdermatol.2009.347 DO - 10.1001/archdermatol.2009.347 ID - Lecluse2010 ER - TY - STD TI - Ritchlin CT, Merola JF, Gellett AM, Lin CY, Muram T. Anti-drug antibodies, efficacy, and impact of concomitant methotrexate in ixekizumab-treated patients with psoriatic arthritis [abstract]. Arthritis Rheumatol. 2018;70 (Suppl 10). https://acrabstracts.org/abstract/anti-drug-antibodies-efficacy-and-impact-of-concomitant-methotrexate-in-ixekizumab-treated-patients-with-psoriatic-arthritis/. Accessed 01 May 2020. UR - https://acrabstracts.org/abstract/anti-drug-antibodies-efficacy-and-impact-of-concomitant-methotrexate-in-ixekizumab-treated-patients-with-psoriatic-arthritis/ ID - ref43 ER -